Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,840	271 Pages	Allied Market Research	October, 2022	ALMR17651927

Best Price Guarantee
Price	from $3,840
Length	271 Pages
Publisher	Allied Market Research
Published Date	October, 2022
SKU	ALMR17651927

Lung Cancer Screening Market By Type (Low-dose computed tomography (LDCT), X-ray), By Age group (50 and older, Below 50), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

The global lung cancer screening market was valued at $879.59 million in 2021, and is projected to reach $1,853.04 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

Lung cancer screening refers to methods for detecting early lung cancer before they cause symptoms at a point where they are more likely to be cured. Lung cancer is the most common type of cancer that begins in the lungs. Cigarette smoking is the main cause of lung cancer. Based on the microscopic appearance, the tumor cells are classified into small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC). The recommended screening test for lung cancer are low-dose computed tomography and X-ray.

The growth of global lung cancer screening market is majorly driven by alarming increase in prevalence of lung cancer across the globe, increase in smoking population, and technological innovations in screening methods. For instance, the American Society of Clinical Oncology (ASCO) in 2020, stated that the lung cancer is the 2nd most common type of cancer in women and men. In addition, rise in efforts taken by government for early stage detection of lung cancer propels the growth of the market.

Furthermore, rise in awareness regarding early stage screening for lung cancer and surge in the incidences of lung cancer are responsible to increase the demand for effective screening tests. These factors are expected to create growth opportunities for the lung cancer screening market during the forecast period.

However, high cost of screening tests and lack of awareness regarding screening techniques in the developing countries are the factors expected to hamper the growth of the market.

The lung cancer screening market is segmented into type, age group, end user, and region. By type, the market is categorized into low-dose computed tomography (LDCT) and X-ray. On the basis of age group, the market is segregated into 50 and older and below 50. By end user, the market is classified into hospitals, diagnostic centers, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global lung cancer screening market are Canon Medical Systems U.S. Inc., Eon Health, Fujifilm Holdings Corporation, General Electric Company (GE Healthcare), Koninklijke Philips N.V., Medtronic Plc, Microsoft Corporation (Nuance Communications, Inc.), Penrad Technologies Inc., Siemens Ag, and Volpara Solutions Limited.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lung cancer screening market analysis from 2021 to 2031 to identify the prevailing lung cancer screening market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the lung cancer screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global lung cancer screening market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Low-dose computed tomography (LDCT)
X-ray

By Age group

50 and older
Below 50

By End User

Hospitals
Type
Public
Private
Diagnostic Centers
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA

Key Market Players

Canon Medical Systems Corporation
Eon Health
FUJIFILM Holdings Corporation
General Electric incorporated (GE Healthcare)
Koninklijke Philips N.V.
Medtronic plc
Nuance Communications, Inc.
Penrad Technologies Inc
Siemens AG (Siemens Healthineers AG)
Volpara Solutions Limited

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

CHAPTER 1:INTRODUCTION: 1.1.Report description; 1.2.Key market segments; 1.3.Key benefits to the stakeholders; 1.4.Research Methodology; 1.4.1.Secondary research; 1.4.2.Primary research; 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY: 2.1.Key findings of the study; 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW: 3.1.Market definition and scope; 3.2.Key findings; 3.2.1.Top investment pockets; 3.3.Porter’s five forces analysis; 3.4.Top player positioning; 3.5.Market dynamics; 3.5.1.Drivers; 3.5.2.Restraints; 3.5.3.Opportunities; 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LUNG CANCER SCREENING MARKET, BY TYPE: 4.1 Overview; 4.1.1 Market size and forecast; 4.2 Low-dose computed tomography (LDCT); 4.2.1 Key market trends, growth factors and opportunities; 4.2.2 Market size and forecast, by region; 4.2.3 Market analysis by country; 4.3 X-ray; 4.3.1 Key market trends, growth factors and opportunities; 4.3.2 Market size and forecast, by region; 4.3.3 Market analysis by country
CHAPTER 5: LUNG CANCER SCREENING MARKET, BY AGE GROUP: 5.1 Overview; 5.1.1 Market size and forecast; 5.2 50 and older; 5.2.1 Key market trends, growth factors and opportunities; 5.2.2 Market size and forecast, by region; 5.2.3 Market analysis by country; 5.3 Below 50; 5.3.1 Key market trends, growth factors and opportunities; 5.3.2 Market size and forecast, by region; 5.3.3 Market analysis by country
CHAPTER 6: LUNG CANCER SCREENING MARKET, BY END USER: 6.1 Overview; 6.1.1 Market size and forecast; 6.2 Hospitals; 6.2.1 Key market trends, growth factors and opportunities; 6.2.2 Market size and forecast, by region; 6.2.3 Market analysis by country; 6.2.4 Hospitals Lung Cancer Screening Market by Type; 6.2.4.1 Public Market size and forecast, by region; 6.2.4.2 Private Market size and forecast, by region; 6.3 Diagnostic Centers; 6.3.1 Key market trends, growth factors and opportunities; 6.3.2 Market size and forecast, by region; 6.3.3 Market analysis by country; 6.4 Others; 6.4.1 Key market trends, growth factors and opportunities; 6.4.2 Market size and forecast, by region; 6.4.3 Market analysis by country
CHAPTER 7: LUNG CANCER SCREENING MARKET, BY REGION: 7.1 Overview; 7.1.1 Market size and forecast; 7.2 North America; 7.2.1 Key trends and opportunities; 7.2.2 North America Market size and forecast, by Type; 7.2.3 North America Market size and forecast, by Age group; 7.2.4 North America Market size and forecast, by End User; 7.2.4.1 North America Hospitals Lung Cancer Screening Market by Type; 7.2.5 North America Market size and forecast, by country; 7.2.5.1 U.S.; 7.2.5.1.1 Market size and forecast, by Type; 7.2.5.1.2 Market size and forecast, by Age group; 7.2.5.1.3 Market size and forecast, by End User; 7.2.5.2 Canada; 7.2.5.2.1 Market size and forecast, by Type; 7.2.5.2.2 Market size and forecast, by Age group; 7.2.5.2.3 Market size and forecast, by End User; 7.2.5.3 Mexico; 7.2.5.3.1 Market size and forecast, by Type; 7.2.5.3.2 Market size and forecast, by Age group; 7.2.5.3.3 Market size and forecast, by End User; 7.3 Europe; 7.3.1 Key trends and opportunities; 7.3.2 Europe Market size and forecast, by Type; 7.3.3 Europe Market size and forecast, by Age group; 7.3.4 Europe Market size and forecast, by End User; 7.3.4.1 Europe Hospitals Lung Cancer Screening Market by Type; 7.3.5 Europe Market size and forecast, by country; 7.3.5.1 Germany; 7.3.5.1.1 Market size and forecast, by Type; 7.3.5.1.2 Market size and forecast, by Age group; 7.3.5.1.3 Market size and forecast, by End User; 7.3.5.2 France; 7.3.5.2.1 Market size and forecast, by Type; 7.3.5.2.2 Market size and forecast, by Age group; 7.3.5.2.3 Market size and forecast, by End User; 7.3.5.3 UK; 7.3.5.3.1 Market size and forecast, by Type; 7.3.5.3.2 Market size and forecast, by Age group; 7.3.5.3.3 Market size and forecast, by End User; 7.3.5.4 Italy; 7.3.5.4.1 Market size and forecast, by Type; 7.3.5.4.2 Market size and forecast, by Age group; 7.3.5.4.3 Market size and forecast, by End User; 7.3.5.5 Spain; 7.3.5.5.1 Market size and forecast, by Type; 7.3.5.5.2 Market size and forecast, by Age group; 7.3.5.5.3 Market size and forecast, by End User; 7.3.5.6 Rest of Europe; 7.3.5.6.1 Market size and forecast, by Type; 7.3.5.6.2 Market size and forecast, by Age group; 7.3.5.6.3 Market size and forecast, by End User; 7.4 Asia-Pacific; 7.4.1 Key trends and opportunities; 7.4.2 Asia-Pacific Market size and forecast, by Type; 7.4.3 Asia-Pacific Market size and forecast, by Age group; 7.4.4 Asia-Pacific Market size and forecast, by End User; 7.4.4.1 Asia-Pacific Hospitals Lung Cancer Screening Market by Type; 7.4.5 Asia-Pacific Market size and forecast, by country; 7.4.5.1 Japan; 7.4.5.1.1 Market size and forecast, by Type; 7.4.5.1.2 Market size and forecast, by Age group; 7.4.5.1.3 Market size and forecast, by End User; 7.4.5.2 China; 7.4.5.2.1 Market size and forecast, by Type; 7.4.5.2.2 Market size and forecast, by Age group; 7.4.5.2.3 Market size and forecast, by End User; 7.4.5.3 Australia; 7.4.5.3.1 Market size and forecast, by Type; 7.4.5.3.2 Market size and forecast, by Age group; 7.4.5.3.3 Market size and forecast, by End User; 7.4.5.4 India; 7.4.5.4.1 Market size and forecast, by Type; 7.4.5.4.2 Market size and forecast, by Age group; 7.4.5.4.3 Market size and forecast, by End User; 7.4.5.5 South Korea; 7.4.5.5.1 Market size and forecast, by Type; 7.4.5.5.2 Market size and forecast, by Age group; 7.4.5.5.3 Market size and forecast, by End User; 7.4.5.6 Rest of Asia-Pacific; 7.4.5.6.1 Market size and forecast, by Type; 7.4.5.6.2 Market size and forecast, by Age group; 7.4.5.6.3 Market size and forecast, by End User; 7.5 LAMEA; 7.5.1 Key trends and opportunities; 7.5.2 LAMEA Market size and forecast, by Type; 7.5.3 LAMEA Market size and forecast, by Age group; 7.5.4 LAMEA Market size and forecast, by End User; 7.5.4.1 LAMEA Hospitals Lung Cancer Screening Market by Type; 7.5.5 LAMEA Market size and forecast, by country; 7.5.5.1 Brazil; 7.5.5.1.1 Market size and forecast, by Type; 7.5.5.1.2 Market size and forecast, by Age group; 7.5.5.1.3 Market size and forecast, by End User; 7.5.5.2 Saudi Arabia; 7.5.5.2.1 Market size and forecast, by Type; 7.5.5.2.2 Market size and forecast, by Age group; 7.5.5.2.3 Market size and forecast, by End User; 7.5.5.3 South Africa; 7.5.5.3.1 Market size and forecast, by Type; 7.5.5.3.2 Market size and forecast, by Age group; 7.5.5.3.3 Market size and forecast, by End User; 7.5.5.4 Rest of LAMEA; 7.5.5.4.1 Market size and forecast, by Type; 7.5.5.4.2 Market size and forecast, by Age group; 7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE: 8.1. Introduction; 8.2. Top winning strategies; 8.3. Product Mapping of Top 10 Player; 8.4. Competitive Dashboard; 8.5. Competitive Heatmap; 8.6. Key developments
CHAPTER 9: COMPANY PROFILES: 9.1 Canon Medical Systems Corporation; 9.1.1 Company overview; 9.1.2 Company snapshot; 9.1.3 Operating business segments; 9.1.4 Product portfolio; 9.1.5 Business performance; 9.1.6 Key strategic moves and developments; 9.2 Eon Health; 9.2.1 Company overview; 9.2.2 Company snapshot; 9.2.3 Operating business segments; 9.2.4 Product portfolio; 9.2.5 Business performance; 9.2.6 Key strategic moves and developments; 9.3 FUJIFILM Holdings Corporation; 9.3.1 Company overview; 9.3.2 Company snapshot; 9.3.3 Operating business segments; 9.3.4 Product portfolio; 9.3.5 Business performance; 9.3.6 Key strategic moves and developments; 9.4 General Electric incorporated (GE Healthcare); 9.4.1 Company overview; 9.4.2 Company snapshot; 9.4.3 Operating business segments; 9.4.4 Product portfolio; 9.4.5 Business performance; 9.4.6 Key strategic moves and developments; 9.5 Koninklijke Philips N.V.; 9.5.1 Company overview; 9.5.2 Company snapshot; 9.5.3 Operating business segments; 9.5.4 Product portfolio; 9.5.5 Business performance; 9.5.6 Key strategic moves and developments; 9.6 Medtronic plc; 9.6.1 Company overview; 9.6.2 Company snapshot; 9.6.3 Operating business segments; 9.6.4 Product portfolio; 9.6.5 Business performance; 9.6.6 Key strategic moves and developments; 9.7 Nuance Communications, Inc.; 9.7.1 Company overview; 9.7.2 Company snapshot; 9.7.3 Operating business segments; 9.7.4 Product portfolio; 9.7.5 Business performance; 9.7.6 Key strategic moves and developments; 9.8 Penrad Technologies Inc; 9.8.1 Company overview; 9.8.2 Company snapshot; 9.8.3 Operating business segments; 9.8.4 Product portfolio; 9.8.5 Business performance; 9.8.6 Key strategic moves and developments; 9.9 Siemens AG (Siemens Healthineers AG); 9.9.1 Company overview; 9.9.2 Company snapshot; 9.9.3 Operating business segments; 9.9.4 Product portfolio; 9.9.5 Business performance; 9.9.6 Key strategic moves and developments; 9.10 Volpara Solutions Limited; 9.10.1 Company overview; 9.10.2 Company snapshot; 9.10.3 Operating business segments; 9.10.4 Product portfolio; 9.10.5 Business performance; 9.10.6 Key strategic moves and developments
LIST OF TABLES: TABLE 1. GLOBAL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 2. LUNG CANCER SCREENING MARKET, FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY REGION, 2021-2031 ($MILLION); TABLE 3. LUNG CANCER SCREENING MARKET FOR LOW-DOSE COMPUTED TOMOGRAPHY (LDCT), BY COUNTRY, 2021-2031 ($MILLION); TABLE 4. LUNG CANCER SCREENING MARKET, FOR X-RAY, BY REGION, 2021-2031 ($MILLION); TABLE 5. LUNG CANCER SCREENING MARKET FOR X-RAY, BY COUNTRY, 2021-2031 ($MILLION); TABLE 6. GLOBAL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 7. LUNG CANCER SCREENING MARKET, FOR 50 AND OLDER, BY REGION, 2021-2031 ($MILLION); TABLE 8. LUNG CANCER SCREENING MARKET FOR 50 AND OLDER, BY COUNTRY, 2021-2031 ($MILLION); TABLE 9. LUNG CANCER SCREENING MARKET, FOR BELOW 50, BY REGION, 2021-2031 ($MILLION); TABLE 10. LUNG CANCER SCREENING MARKET FOR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION); TABLE 11. GLOBAL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 12. LUNG CANCER SCREENING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION); TABLE 13. LUNG CANCER SCREENING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 14. GLOBAL HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 15. LUNG CANCER SCREENING MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION); TABLE 16. LUNG CANCER SCREENING MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION); TABLE 17. LUNG CANCER SCREENING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($MILLION); TABLE 18. LUNG CANCER SCREENING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 19. LUNG CANCER SCREENING MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION); TABLE 20. LUNG CANCER SCREENING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION); TABLE 21. LUNG CANCER SCREENING MARKET, BY REGION, 2021-2031 ($MILLION); TABLE 22. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 23. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 24. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 25. NORTH AMERICA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 26. NORTH AMERICA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 27. U.S. LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 28. U.S. LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 29. U.S. LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 30. CANADA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 31. CANADA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 32. CANADA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 33. MEXICO LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 34. MEXICO LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 35. MEXICO LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 36. EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 37. EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 38. EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 39. EUROPE HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 40. EUROPE LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 41. GERMANY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 42. GERMANY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 43. GERMANY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 44. FRANCE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 45. FRANCE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 46. FRANCE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 47. UK LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 48. UK LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 49. UK LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 50. ITALY LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 51. ITALY LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 52. ITALY LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 53. SPAIN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 54. SPAIN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 55. SPAIN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 56. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 57. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 58. REST OF EUROPE LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 59. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 60. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 61. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 62. ASIA-PACIFIC HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 63. ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 64. JAPAN LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 65. JAPAN LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 66. JAPAN LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 67. CHINA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 68. CHINA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 69. CHINA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 70. AUSTRALIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 71. AUSTRALIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 72. AUSTRALIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 73. INDIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 74. INDIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 75. INDIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 76. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 77. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 78. SOUTH KOREA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 79. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 80. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 81. REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 82. LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 83. LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 84. LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 85. LAMEA HOSPITALS LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 86. LAMEA LUNG CANCER SCREENING MARKET, BY COUNTRY, 2021-2031 ($MILLION); TABLE 87. BRAZIL LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 88. BRAZIL LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 89. BRAZIL LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 90. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 91. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 92. SAUDI ARABIA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 93. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 94. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 95. SOUTH AFRICA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 96. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY TYPE, 2021-2031 ($MILLION); TABLE 97. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY AGE GROUP, 2021-2031 ($MILLION); TABLE 98. REST OF LAMEA LUNG CANCER SCREENING MARKET, BY END USER, 2021-2031 ($MILLION); TABLE 99.CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT; TABLE 100.CANON MEDICAL SYSTEMS CORPORATION: OPERATING SEGMENTS; TABLE 101.CANON MEDICAL SYSTEMS CORPORATION: PRODUCT PORTFOLIO; TABLE 102.CANON MEDICAL SYSTEMS CORPORATION: NET SALES,; TABLE 103.CANON MEDICAL SYSTEMS CORPORATION: KEY STRATERGIES; TABLE 104.EON HEALTH: COMPANY SNAPSHOT; TABLE 105.EON HEALTH: OPERATING SEGMENTS; TABLE 106.EON HEALTH: PRODUCT PORTFOLIO; TABLE 107.EON HEALTH: NET SALES,; TABLE 108.EON HEALTH: KEY STRATERGIES; TABLE 109.FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT; TABLE 110.FUJIFILM HOLDINGS CORPORATION: OPERATING SEGMENTS; TABLE 111.FUJIFILM HOLDINGS CORPORATION: PRODUCT PORTFOLIO; TABLE 112.FUJIFILM HOLDINGS CORPORATION: NET SALES,; TABLE 113.FUJIFILM HOLDINGS CORPORATION: KEY STRATERGIES; TABLE 114.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): COMPANY SNAPSHOT; TABLE 115.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): OPERATING SEGMENTS; TABLE 116.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): PRODUCT PORTFOLIO; TABLE 117.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): NET SALES,; TABLE 118.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE): KEY STRATERGIES; TABLE 119.KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT; TABLE 120.KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS; TABLE 121.KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO; TABLE 122.KONINKLIJKE PHILIPS N.V.: NET SALES,; TABLE 123.KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES; TABLE 124.MEDTRONIC PLC: COMPANY SNAPSHOT; TABLE 125.MEDTRONIC PLC: OPERATING SEGMENTS; TABLE 126.MEDTRONIC PLC: PRODUCT PORTFOLIO; TABLE 127.MEDTRONIC PLC: NET SALES,; TABLE 128.MEDTRONIC PLC: KEY STRATERGIES; TABLE 129.NUANCE COMMUNICATIONS, INC.: COMPANY SNAPSHOT; TABLE 130.NUANCE COMMUNICATIONS, INC.: OPERATING SEGMENTS; TABLE 131.NUANCE COMMUNICATIONS, INC.: PRODUCT PORTFOLIO; TABLE 132.NUANCE COMMUNICATIONS, INC.: NET SALES,; TABLE 133.NUANCE COMMUNICATIONS, INC.: KEY STRATERGIES; TABLE 134.PENRAD TECHNOLOGIES INC: COMPANY SNAPSHOT; TABLE 135.PENRAD TECHNOLOGIES INC: OPERATING SEGMENTS; TABLE 136.PENRAD TECHNOLOGIES INC: PRODUCT PORTFOLIO; TABLE 137.PENRAD TECHNOLOGIES INC: NET SALES,; TABLE 138.PENRAD TECHNOLOGIES INC: KEY STRATERGIES; TABLE 139.SIEMENS AG (SIEMENS HEALTHINEERS AG): COMPANY SNAPSHOT; TABLE 140.SIEMENS AG (SIEMENS HEALTHINEERS AG): OPERATING SEGMENTS; TABLE 141.SIEMENS AG (SIEMENS HEALTHINEERS AG): PRODUCT PORTFOLIO; TABLE 142.SIEMENS AG (SIEMENS HEALTHINEERS AG): NET SALES,; TABLE 143.SIEMENS AG (SIEMENS HEALTHINEERS AG): KEY STRATERGIES; TABLE 144.VOLPARA SOLUTIONS LIMITED: COMPANY SNAPSHOT; TABLE 145.VOLPARA SOLUTIONS LIMITED: OPERATING SEGMENTS; TABLE 146.VOLPARA SOLUTIONS LIMITED: PRODUCT PORTFOLIO; TABLE 147.VOLPARA SOLUTIONS LIMITED: NET SALES,; TABLE 148.VOLPARA SOLUTIONS LIMITED: KEY STRATERGIES
LIST OF FIGURES: FIGURE 1.LUNG CANCER SCREENING MARKET SEGMENTATION; FIGURE 2.LUNG CANCER SCREENING MARKET,2021-2031; FIGURE 3.LUNG CANCER SCREENING MARKET,2021-2031; FIGURE 4. TOP INVESTMENT POCKETS, BY REGION; FIGURE 5.PORTER FIVE-1; FIGURE 6.PORTER FIVE-2; FIGURE 7.PORTER FIVE-3; FIGURE 8.PORTER FIVE-4; FIGURE 9.PORTER FIVE-5; FIGURE 10.TOP PLAYER POSITIONING; FIGURE 11.LUNG CANCER SCREENING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES; FIGURE 12.LUNG CANCER SCREENING MARKET,BY TYPE,2021(%); FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 14.COMPARATIVE SHARE ANALYSIS OF X-RAY LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 15.LUNG CANCER SCREENING MARKET,BY AGE GROUP,2021(%); FIGURE 16.COMPARATIVE SHARE ANALYSIS OF 50 AND OLDER LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 17.COMPARATIVE SHARE ANALYSIS OF BELOW 50 LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 18.LUNG CANCER SCREENING MARKET,BY END USER,2021(%); FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS LUNG CANCER SCREENING MARKET,2021-2031(%); FIGURE 22.LUNG CANCER SCREENING MARKET BY REGION,2021; FIGURE 23.U.S. LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 24.CANADA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 25.MEXICO LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 26.GERMANY LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 27.FRANCE LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 28.UK LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 29.ITALY LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 30.SPAIN LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 31.REST OF EUROPE LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 32.JAPAN LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 33.CHINA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 34.AUSTRALIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 35.INDIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 36.SOUTH KOREA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 37.REST OF ASIA-PACIFIC LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 38.BRAZIL LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 39.SAUDI ARABIA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 40.SOUTH AFRICA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 41.REST OF LAMEA LUNG CANCER SCREENING MARKET,2021-2031($MILLION); FIGURE 42. TOP WINNING STRATEGIES, BY YEAR; FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT; FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY; FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS; FIGURE 46.COMPETITIVE DASHBOARD; FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS; FIGURE 48.CANON MEDICAL SYSTEMS CORPORATION.: NET SALES ,($MILLION); FIGURE 49.EON HEALTH.: NET SALES ,($MILLION); FIGURE 50.FUJIFILM HOLDINGS CORPORATION.: NET SALES ,($MILLION); FIGURE 51.GENERAL ELECTRIC INCORPORATED (GE HEALTHCARE).: NET SALES ,($MILLION); FIGURE 52.KONINKLIJKE PHILIPS N.V..: NET SALES ,($MILLION); FIGURE 53.MEDTRONIC PLC.: NET SALES ,($MILLION); FIGURE 54.NUANCE COMMUNICATIONS, INC..: NET SALES ,($MILLION); FIGURE 55.PENRAD TECHNOLOGIES INC.: NET SALES ,($MILLION); FIGURE 56.SIEMENS AG (SIEMENS HEALTHINEERS AG).: NET SALES ,($MILLION); FIGURE 57.VOLPARA SOLUTIONS LIMITED.: NET SALES ,($MILLION)